Table 2.
Importance of suggestions to reduce off-label prescribing (number of GPs (%))
| ++ | + | / | − | −− | Median | |
|---|---|---|---|---|---|---|
| Increased paediatric clinical trials for new drugs | 64 (32.8) | 90 (46.2) | 35 (17.9) | 5 (2.6) | 1 (0.5) | + |
| Paediatric clinical trials for existing drugs | 59 (29.9) | 92 (46.7) | 41 (20.8) | 4 (2.0) | 1 (0.5) | + |
| Appropriate formulations for young children | 103 (51.5) | 91 (45.5) | 6 (3.0) | 0 (0.0) | 0 (0.0) | ++ |
| More consistent and clearer dosage information | 124 (62.0) | 71 (35.5) | 5 (2.5) | 0 (0.0) | 0 (0.0) | ++ |
++ very important, + important,/moderate, – unimportant, –– very unimportant.